He and She Health, Inc. (NYSE: HIM) investors will be delighted, with the company posting good numbers with its latest results. It was an overall positive result, with revenue beating expectations by 4.9% to $402 million. Hims & Hers Health also reported statutory profit of US$0.32, an impressive 534% above analyst forecasts. Earnings are an important time for investors because they can track a company’s performance, look at analyst forecasts for next year, and see if there has been a change in sentiment towards the company. ‘business. Readers will be happy to know that we’ve aggregated the latest statutory forecasts to see if analysts have changed their minds on Hims & Hers Health after the latest results.

Check out our latest analysis on him and his health.

Taking into account the latest results, the current consensus of Hims & Hers Health’s twelve analysts is for revenue of US$2.04 billion in 2025. This would reflect a whopping 64% increase in its revenue in the over the last 12 months. Statutory earnings per share are expected to be US$0.46, roughly flat over the trailing 12 months. Prior to this earnings report, analysts were forecasting revenues of US$1.87 billion and earnings per share (EPS) of US$0.41 in 2025. There has been a fairly notable increase in sentiment, analysts increasing revenues and achieving a substantial gain in earnings per share. share in particular.

It will come as no surprise to learn that the analysts have increased their price target for Hims & Hers Health by 11% to US$24.17 on the back of these upgrades. There is, however, another way to look at price targets, and that is the range of price targets offered by analysts, because a wide range of estimates could suggest a diverse view of possible outcomes for the business. The most optimistic Hims & Hers Health analyst has a price target of US$32.00 per share, while the most pessimistic values ​​it at US$16.00. This is a fairly wide range of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the company.

One way to get more context on these forecasts is to look at how they compare to past performance and how other companies of the same type industry are efficient. The period through the end of 2025 will be the same, according to analysts, with revenue forecasts expected to show 48% growth on an annualized basis. This matches its 50% annual growth over the past five years. In contrast, our data suggests that other companies (covered by analysts) in a similar industry are expected to see revenue grow 6.7% annually. So while Hims & Hers Health is expected to maintain its revenue growth rate, it is certainly expected to grow faster than the broader industry.

The story continues